Positively charged templates for labeling internalizing antibodies:: comparison of N-succinimidyl 5-Iodo-3-pyridinecarboxylate and the D-amino acid peptide KRYRR

被引:19
作者
Foulon, CF
Welsh, PC
Bigner, DD
Zalutsky, MR
机构
[1] Duke Univ, Med Ctr, Dept Radiol, Durham, NC 27710 USA
[2] Duke Univ, Med Ctr, Dept Pathol, Durham, NC 27710 USA
关键词
radioiodination; epidermal growth factor receptor; monoclonal antibodies; radioimmunotherapy;
D O I
10.1016/S0969-8051(01)00239-6
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Receptor-mediated internalization of monoclonal antibodies (mAbs), such as those specific for the epidermal growth factor receptor variant III (EGFRvIII), can lead to rapid loss of radioactivity from the target cell. In the current study, the anti-EGFRvIII mAb L8A4 was radioiodinated using two methods -N-succinimidyl 5-iodo-3-pyridinecarboxylate (SIPC) and via a D-amino acid peptide LysArgTyrArgArg (D-KRYRR). Paired-label internalization assays performed on EGFRvIII-expressing U87 Delta EGFR cells in vitro demonstrated that labeling L8A4 using D-KRYRR resulted in significantly higher retention of radioiodine in the intracellular compartment. In athymic mice with D256 human glioma xenografts, tumor uptake was similar for both labeling methods through 24 hr. However, an up to fourfold higher tumor retention was observed for mAb labeled with the D-amino acid peptide at later time points. Radiation absorbed dose calculations based on these biodistribution data indicated that L8A4 labeled using D-KRYRR exhibited better tumor-to-normal-organ radiation dose ratios, suggesting that this labeling method may be of particular value for labeling internalizing mAbs. (C) 2001 Elsevier Science Inc. All rights reserved.
引用
收藏
页码:769 / 777
页数:9
相关论文
共 29 条
[21]   The new wave in robot learning [J].
Sharkey, NE .
ROBOTICS AND AUTONOMOUS SYSTEMS, 1997, 22 (3-4) :179-185
[22]  
STEIN R, 1995, CANCER RES, V55, P3132
[23]  
Stein R, 1997, J NUCL MED, V38, P391
[24]  
VAIDYANATHAN G, 2001, IN PRESS BIOCONJUGAT
[25]  
WIKSTRAND CJ, 1995, CANCER RES, V55, P3140
[26]   The class III variant of the epidermal growth factor receptor (EGFRvIII): characterization and utilization as an immunotherapeutic targets [J].
Wikstrand, CJ ;
Reist, CJ ;
Archer, GE ;
Zalutsky, MR ;
Bigner, DD .
JOURNAL OF NEUROVIROLOGY, 1998, 4 (02) :148-158
[27]  
Wikstrand CJ, 1997, CANCER RES, V57, P4130
[28]  
Zalutsky M R, 1997, Q J Nucl Med, V41, P71
[29]  
ZALUTSKY MR, 1989, CANCER RES, V49, P5543